Abstract:Background: Fibronectin (FN) can improve organ function and slow the progression of sepsis, but full-length FN is hard to be exacted as a therapeutic. Objective: This study aimed to investigate the beneficial effects of C-terminal heparin-binding domain polypeptide of FN (rhFNHC-36) in a cecal ligation and puncture (CLP)-mediated murine septic model and explore its regulatory effects on macrophages. Methods: Mice were randomly assigned to four groups: unoperated control (Normal), sham operation control (Sham), CLP-operation with intravenous injection of phosphate-buffered saline (CLP+PBS), and CLP-operation with rhFNHC-36 treatment (CLP+rhFNHC-36). Blood and abdominal fluid samples were subjected to bacterial colony formation assays. Organs (liver, spleen, and lung) were undergone histopathological analyses and/or weighed to obtain organ indices. Serum interleukin-6 (IL-6) levels, nitric oxide (NO) release from isolated abdominal macrophages, and chemotactic effect of macrophages were measured with commercial kits. Surface programmed death ligand 1 (PD-L1) expression on macrophages was measured by flow cytometry. Results: Mice in the CLP+PBS group showed a lower survival rate than that in the CLP+rhFNHC-36 group. Improved survival was associated with better clearance of bacterial pathogens, as evidenced by colony formation assays. The CLP-induced decrease in thymus and spleen indices was attenuated by rhFNHC-36 treatments. rhFNHC-36 alleviated sepsis-associated tissue damage in liver, spleen, and lung. CLP-mediated increases in plasma IL-6 levels were reversed by rhFNHC-36 treatment. NO levels in peritoneal macrophages after lipopolysaccharides (LPS)-stimulation in the CLP+rhFNHC-36 group were lower than that in the CLP+PBS group. Notably, macrophages from the CLP+rhFNHC-36 group retained better chemotaxis ability. After LPS challenge, these macrophages had a reduced percentage of PD-L1-positive cells compared to those in the CLP+PBS group. Conclusion: rhFNHC-36 improved survival of mice with CLP-induced sepsis by reducing tissue damage and modulating macrophage function. Our work provides critical insight for developing FN-based and macrophages-targeted therapeutics for treating sepsis.

Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor

The Fab Fragment of a Human Anti-Siglec-9 Monoclonal Antibody Suppresses LPS-Induced Inflammatory Responses in Human Macrophages

A functional CATTn microsatellite in the promoter of macrophage migration inhibitory factor in sepsis

Α-Mangostin Suppresses NLRP3 Inflammasome Activation Via Promoting Autophagy in LPS-stimulated Murine Macrophages and Protects Against CLP-induced Sepsis in Mice

Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-like Receptor 4.

Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis

Sphingosine 1-Phosphate Receptor-3 Contributes to Host Defense Against Polymicrobial Sepsis Via Modulating Macrophage Chemotaxis (CAM4P.161)

C-Terminal Fibronectin Exerts Beneficial Effects in Reducing Tissue Damage and Modulating Macrophage Function in a Murine Septic Model

Increased Susceptibility of S1PR3-Deficient Mice to Escherichia Coli Sepsis is Associated with an Impaired Bactericidal Activity in Macrophage

Identification of tetranectin-targeting monoclonal antibodies to treat potentially lethal sepsis

Mycophenolate Mofetil Protects Septic Mice Via the Dual Inhibition of Inflammatory Cytokines and PD-1

C-176 inhibits macrophage polarization towards M1-subtype and ameliorates LPS induced acute kidney injury

LECT2 Protects Mice Against Bacterial Sepsis by Activating Macrophages Via the CD209a Receptor.

Expression and Characterization of Recombinant Human Milk Fat Globule-Egf Factor VIII.

The Therapeutic Effect of an Anti-TNF-α/HSA/IL-6R Triple-Specific Fusion Protein Under Experimental Septic Conditions

MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model

A novel opsonic eCIRP inhibitor for lethal sepsis

Inhibitory mechanisms of decoy receptor 3 in cecal ligation and puncture-induced sepsis

A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis

A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.

Monoclonal Antibody Targeting Staphylococcus Aureus Surface Protein A (sasa) Protect Against Staphylococcus Aureus Sepsis and Peritonitis in Mice.